Optimized variants of the broadly neutralizing HIV-1 gp41 antibody, 10E8

Optimized variants broadly neutralizing HIV-1 gp41 antibody, 10E8, exhibit improved manufacturing properties, while preserving neutralizing breadth and potency.

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) recently discovered a human neutralizing antibody, 10E8, that binds to the GP41 protein of HIV-1 and prevents infection by HIV-1.  10E8 potently neutralizes up to 98% of genetically diverse HIV-1 strains. 

By engineering the 10E8 antibody, NIAID scientists have improved the properties of 10E8 that affect manufacturability, such as solubility, while preserving its neutralizing breadth and potency. 

10E8 variants are useful for passive protection from infection, as therapeutics, and as a tool for vaccine development. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404.


Potential Commercial Applications: 

  • Passive protection to prevent HIV infection

  • Passive protection to prevent mother-to-infant HIV transmission

  • Gene-based vectors for anti-gp41 antibody expression

  • Therapeutics for elimination of HIV infected cells that are actively producing virus

Competitive Advantages: 

  • Among the most potent and broadly neutralizing human antibodies isolated to date  

  • Broad reactivity and high affinity to most HIV-1 strains  

  • Improved manufacturability relative to the natural 10E8 antibody

Development Stage: 

  • In vivo data available (animal)

     

Inventors:  Peter D. Kwong (NIAID), Young Do Kwon (NIAID), Ivelin S. Georgiev (NIAID), Gilad A. Ofek (NIAID), Baoshan Zhang (NIAID), Krisha McKee (NIAID), John Mascola (NIAID), Gwo-Yu  Chuang (NIAID), Sijy O’Dell (NIAID), Robert Bailer (NIAID), Mark Louder (NIAID), Mangaiarkarasi Asokan (NIAID), Richard Schwartz (NIAID), Jonathan Cooper (NIAID), Kevin Carlton (NIAID), Michael Bender (NIAID), Mark Connors (NIAID), Amarendra Pegu (NIAID), Lisa Kueltzo (NIAID), Tatyana Gindin (Columbia University), and Lawrence Shapiro (Columbia University).

Intellectual Property:
US Application No. 62/250,360
PCT Application No. PCT/US2016/060390
US Application No. 15/772,443
CA Application No. 3003878
CN Application No. 201680077520.X
EP Application No. 16801639.2
IN Application No. 201837016184
ZA Application No. 2018/02875
AU Application No. 2016349392

Publications:
Kwon YD, et al. PMID 27053554

Licensing Contact:
Vince Contreras, Ph.D.
Email: vincent.contreras@nih.gov
Phone: 240-669-2823

Licensing Contact:  Dr. Vince Contreras, 240-669-2823; vince.contreras@nih.gov

 

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.